Kelyniam Global, Inc. (OTC:KLYG) is an advanced design, engineering, manufacturing and rapid prototyping company specializing in the use of CADCAM (Computer Aided Design Computer Aided Manufacturing) technology. KLYG will be manufacturing artificial bone implants for cranial, orthopedic, dental and cosmetic medical applications from FDA approved polymers (which is summarized in a nine minute new medical video at the Company's website:
http://www.kelyniam.com/video.wmv ).
The Company's medical technology process starts with CT scan data (e.g. cranial bones), which is converted to CADCAM data to drive machines in the creation of high precision replicas of bones within a 4-6 hour turnaround time. The bone replicas are produced with a hard plastic material with a fit/function that is accepted by the body and the process could be expanded to dental implants, cosmetic medicine, and other areas such as customized eye glasses.
The CT scan data allows technicians to recreate a 3-dimensional CAD model of the patient's skull, which is utilized by the Company's engineers to make a highly accurate model that is used by the medical supplier to create a bio-compatible implant to replace the damaged area of the patient. Accounting for the time it takes to get the scans from the doctors, a patient can have an implant that is a near perfect replacement of the damaged area within a matter of days.
KLYG was previously working with a major medical supplier for the Bio-CADCAM cranial implants, but has recently researched and developed an entirely new process on their own using FDA approved polymers. The custom cranial bone implants will be sold by Kelyniam's medical supply partners, representing a nearly exact replica of human cranial bones with accuracy levels within 10-20/1000 inch. Related applications would likely include other bones (e.g. arms and legs) as well as hip replacements.
Last June, KLYG acquired M2-Systems, which became the Engineering and Stereo Lithography Divisions of the Company and is located in New Britain, CT. The Company's Engineering and Stereo Lithography Divisions serve a wide range of clients from industry groups that include automotive, aerospace, jewelry, nautical, and consumer products. The recent developments in Bio-CADCAM technology outlined above offer a significant market opportunity to apply this technology to dental and medical applications.
The Company's acquisition of M2-Systems gives KLYG a complete Rapid Prototyping and Engineering facility located in New Britain, CT. KLYG recently appointed Bernard Hochstetter to lead the Company's medical implant sales team. Mr. Hochstetter has experience with obtaining new medical product approvals with regulatory agencies such as the FDA, along with a science and law educational background.
The Company caused to be in effect a two for one (2:1) forward stock split, for a second time since its inception, with the certificates of record as of March 4, 2009. As will be reflected in the first quarterly report for 2009, the Company’s authorized share count is 20 million with 19.3 million currently outstanding – including 95% ownership by executives and directors of KLYG. Along with improving operating results since the M2 acquisition, the potential market demand for artificial bone implants for cranial, orthopedic, dental and cosmetic medical applications that the Company will be manufacturing from FDA approved polymers could make 2009 a breakout year for KLYG.
Disclosure: No position.
$0.46 (04/24/09)
